VivoSeq
Musculoskeletal

Myofascial Pain Syndrome

13

Pipeline Programs↗

5

Active Trials↗

11

Companies Involved↗

Myofascial Pain Syndrome is an emerging landscape with 13 programs across 11 companies. The most active players are Vitae Pharmaceuticals Inc., an Allergan affiliate, Averitas Pharma, Inc., Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. 6 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

11/100

Mech. Concentration

22/100

Completion Rate

91/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

V

Vitae Pharmaceuticals Inc., an Allergan affiliate

1 program

Phase 3A

Averitas Pharma, Inc.

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedNovartis logo

Novartis

1 program

ApprovedC

Citius Pharmaceuticals, Inc.

1 program

ApprovedS

Scilex Pharmaceuticals, Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

20

clinical trials

Completed10 · 50%
Unknown status4 · 20%
Recruiting3 · 15%
Terminated1 · 5%
Enrolling by invitation1 · 5%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

20 trials

The Therapeutic Effects of Dextrose Injection for Myofascial Pain Syndrome
Recruiting·NNational Cheng-Kung University Hospital·N/A·NCT05429827·30 enrolled
Trigger Point Injection for Myofascial Pain Syndrome in the Low Back: A Randomized Controlled Trial
Recruiting·MMadigan Army Medical Center·Phase 4·NCT04704297·180 enrolled
Determining the Predictors of Treatment Expectations in Individuals With Myofascial Pain Syndrome: A Cross-Sectional Study
Recruiting·KKTO Karatay University·N/A·NCT07689396·85 enrolled
Effectiveness of Second-Generation Focused Extracorporeal Shockwave Therapy Combined With Ultrasonographic Assessment in Myofascial Pain Syndrome of the Neck and Shoulder: A Pilot Randomized Controlled Trial
Not yet recruiting·Cishan Hospital, Ministry of Health and Welfare·Preclinical·NCT07660523·60 enrolled
Extended Therapeutic Effect of 35kDa Hyaluronan Fragment Injection in Patients With Chronic Pain Caused by Myofascial Pain Syndrome
Enrolling by invitation·NNakhia Impex LLC·N/A·NCT06444035·10 enrolled
Effect of Lidocaine Phonophoresis Versus Pulsed Ultrasound on Myofascial Pain Syndrome in Athletic Children
Completed·—·Phase 1·NCT04185194·50 enrolled
Comparison of NSAID Patch Given in Monotherapy and NSAID Patch in Combination With Transcutaneous Electric Nerve Stimulation, Heating Pad, or Topical Capsaicin in the Treatment of Patients With Myofascial Pain Syndrome of the Upper Trapezius: A Pilot Study
Completed·YYonsei University·N/A·NCT01884116·100 enrolled
Does Botulinum Toxin Type-A Injection an Effective Way of Relieving Pain in Myofascial Pain Syndrome Patients or Not
Completed·—·N/A·NCT06899438·38 enrolled
Study to Assess the Efficacy and Safety of Dysport® in Upper Back Myofascial Pain Syndrome
Completed·Ipsen logoIpsen·Phase 2·NCT00134810·381 enrolled
Hyaluronidase for Trigger Point Injection in Myofascial Pain Syndrome
Completed·SSamsung Medical Center·N/A·NCT02293083·61 enrolled
Botulinum Toxin Type A (Dysport) Associated With Rehabilitation Treatment in Patients With Primary Myofascial Pain Syndrome
Completed·Ipsen logoIpsen·Phase 2·NCT00149240·24 enrolled
Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy.
Completed·GGrupo Rehabilitacion en Salud·Phase 4·NCT01250184·127 enrolled
A Study of the Combination of Electrical Stimulation and Dysport® in Myofascial Pain Syndrome.
Completed·Ipsen logoIpsen·Phase 3·NCT00246142·76 enrolled
The Use of Botulinum Toxin in the Management of Myofascial Pain Syndrome
Completed·—·Phase 1/2·NCT06824324·14 enrolled
Comparison of the Effectiveness of Dry Needling and Cupping Therapy in Patients With Myofascial Pain Syndrome: A Randomized Trial
Completed·TTurkish League Against Rheumatism·Preclinical·NCT07688317·92 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)